What does the acquisition mean for Hologic stockholders?
Hologic stockholders will receive $76 per share in cash, plus a contingent value right of up to $3 per share based on revenue milestones.
Finance / Mergers and Acquisitions
Hologic, Inc. (Nasdaq: HOLX) has announced its acquisition by funds managed by Blackstone and TPG in a deal valued at up to $79 per share, translating to an enterprise value of up to $18.3 billion. This acquisition aims to bolster Hologic's...
The acquisition is structured such that Hologic stockholders will receive $76 per share in cash, along with a contingent value right (CVR) that could add up to $3 per share. These CVR payments are tied to Hologic’s Breast Health business achieving specific revenue targets in fiscal years 2026 and 2027.
This deal is expected to close in the first half of calendar year 2026, pending Hologic’s stockholders' approval, regulatory approvals, and other customary closing conditions. Upon completion, Hologic’s common stock will be delisted from the Nasdaq stock market, though the company will maintain its headquarters in Marlborough, Massachusetts, and continue to operate under the Hologic name.
The merger agreement also includes a 45-day 'go-shop' period, allowing Hologic to solicit alternative acquisition proposals. Goldman Sachs & Co. LLC is serving as the financial advisor to Hologic, while Citi is advising the Blackstone-and-TPG consortium.
Hologic stockholders will receive $76 per share in cash, plus a contingent value right of up to $3 per share based on revenue milestones.
The transaction is expected to close in the first half of calendar year 2026, subject to stockholder and regulatory approvals.
Yes, Hologic will maintain its headquarters and continue to operate under the Hologic name and brand.
What are your thoughts on the potential impact of this acquisition on the future of women's health technologies? Share this article with others who need to stay ahead of this trend!
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.